Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation.

Thyroid : official journal of the American Thyroid Association - 1 Jun 2010

Cho Nancy L, Lin Chi-Iou, Whang Edward E, Carothers Adelaide M, Moore Francis D, Ruan Daniel T

Abstract excerpt

BACKGROUND: Activation of the Wnt/beta-catenin signaling pathway is implicated in thyroid tumorigenesis, and up to 90% of papillary thyroid cancer (PTC) demonstrate aberrant expression of beta-catenin. Nonsteroidal antiinflammatory drugs reverse aberrant beta-catenin expression and localization in colon cancer. In this study, we tested the hypothesis that the nonsteroidal antiinflammatory drug sulindac would...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Papillary
Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Gland

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 20470206
DOI: 10.1089/thy.2009.0415

Genes

BRAF
RET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation.PMID 20470206Read ↗

Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell linesSemantic proximity Read ↗

Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.Semantic proximity Read ↗

Niclosamide is a potential therapeutic for familial adenomatosis polyposis by disrupting Axin-GSK3 interactionSemantic proximity Read ↗

Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC.Semantic proximity Read ↗

Tumors from rats given 1,2-dimethylhydrazine plus chlorophyllin or indole-3-carbinol contain transcriptional changes in beta-catenin that are independent of beta-catenin mutation status.Semantic proximity Read ↗

Effect of nonsteroidal anti-inflammatory drugs on β-catenin protein levels and catenin-related transcription in human colorectal cancer cellsSemantic proximity Read ↗

The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells.Semantic proximity Read ↗

Inhibition of beta-catenin/Tcf signaling by flavonoids.Semantic proximity Read ↗

Anti-helminthic niclosamide inhibits Ras-driven oncogenic transformation via activation of GSK-3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.